Matinas BioPharma Holdings (MTNB) Cash from Investing Activities (2013 - 2025)
Matinas BioPharma Holdings (MTNB) posted quarterly Cash from Investing Activities of $15000.0 for Q4 2025, down 97.0% year-over-year from $500000.0 in Q4 2024, and down 97.0% quarter-over-quarter from $500000.0 in Q4 2024.
Matinas BioPharma Holdings (MTNB) Cash from Investing Activities (2013 - 2025) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Cash from Investing Activities for 12 consecutive years, with $15000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Investing Activities fell 97.0% year-over-year to $15000.0; the TTM figure through Dec 2025 stood at $7.2 million (down 21.56% YoY), while the FY2025 annual figure was $335000.0, down 96.36% from the prior year.
- Cash from Investing Activities slipped to $15000.0 in Q4 2025 per MTNB's latest filing, from $500000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $9.6 million in Q3 2024 and bottomed at -$3.8 million in Q2 2022.
- Historically, Cash from Investing Activities has averaged $2.6 million across 5 years, with a median of $2.0 million in 2024.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 174.14% — and 2023, when it jumped 7147.62%.
- Matinas BioPharma Holdings' Cash from Investing Activities stood at $56653.0 in 2021, then plunged by 174.14% to -$42000.0 in 2022, then surged by 7147.62% to $3.0 million in 2023, then tumbled by 83.11% to $500000.0 in 2024, then tumbled by 97.0% to $15000.0 in 2025.
- Business Quant data shows MTNB's Cash from Investing Activities at $15000.0 in Q4 2025, $500000.0 in Q4 2024, and $9.6 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 9.65 Mn |
| Sep 30, 2024 | 9.65 Mn |
| Jun 30, 2024 | -2.94 Mn |
| Jun 30, 2024 | -2.94 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Dec 31, 2023 | 2.96 Mn |
| Dec 31, 2023 | 2.96 Mn |
| Sep 30, 2023 | 1.08 Mn |
| Sep 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 6.20 Mn |
| Jun 30, 2023 | 6.20 Mn |
| Mar 31, 2023 | 3.00 Mn |
| Mar 31, 2023 | 3.00 Mn |
| Dec 31, 2022 | -42,000.00 |
| Dec 31, 2022 | -42,000.00 |